Table 1.
Derivation atezolizumab data (n = 405) | Validation | ||
---|---|---|---|
avelumab data (n = 242) | durvalumab data (n = 198) | ||
Age (years) | |||
Median (min; max) | 66 (32; 89) | 68 (30; 89) | 67 (34; 88) |
Gender | |||
Male | 313 (77.3%) | 175 (72.3%) | 142 (71.7%) |
NLR (Neutrophil / Lymphocyte Ratio) | |||
Missing n (%) | --- | --- | 4 (2.0%) |
ECOG-Performance Status | |||
≥1 | 251 (62.0%) | 158 (65.3%) | 135 (68.2%) |
Serum LDH (U/L) | |||
Missing n (%) | 19 (4.7%) | 7 (2.9%) | 6 (3.0%) |
Platelet counts (109/L) | |||
Missing n (%) | --- | --- | 4 (2.0%) |
Location of Metastasis* | |||
Soft tissue/lymph node | 88 (21.7%) | 55 (22.7%) | 24 (12.1%) |
Serum Albumin (gm/L) | |||
Missing n (%) | --- | --- | 3 (1.5%) |
Hemoglobin (gm/L) | |||
Missing n (%) | --- | --- | 4 (2.0%) |
Number of previous agents | |||
≥ 3 | 104 (25.7%) | 81 (33.5%) | 16 (8.1%) |
atezolizumab and avelumab datasets: Liver metastasis = liver (+/−other), visceral metastasis = visceral (non-liver, +/− soft tissue/lymph node), soft tissue/lymph node metastasis = soft tissue/lymph node (non-liver, non-visceral); durvalumab dataset: Liver metastasis = liver (+/−other), visceral metastasis = visceral (any non-lymph node metastasis including liver, soft tissue and other visceral metastasis), soft tissue/lymph node metastasis = lymph node metastasis only